1例伊布替尼治疗B幼淋巴细胞白血病病例分析并文献复习  

Ibutilinib in the Treatment of B-Cell Lymphoblastic Leukemia:Analysis of a Case and Literature Review

作　　者：王林月 白凤霞[1] 张宇尘 罗云[1] 娄世锋[1] WANG Linyue;BAI Fengxia;ZHANG Yuchen;LUO Yun;LOU Shifeng(Department of Hematology,The Second Afiliated Hospital of Chongying Medical Unitersity,Chongqing,China 40010)

机构地区：[1]重庆医科大学附属第二医院血液科,重庆400010

出　　处：《中国药业》2020年第24期39-41,共3页China Pharmaceuticals

基　　金：重庆市社会事业与民生保障科技创新专项[cstc2017shmsA130084]。

摘　　要：目的探讨伊布替尼在复发难治B幼淋巴细胞白血病(B-PLL)治疗中的作用。方法回顾性分析1例B-PLL患者的临床表现、骨髓细胞形态学及免疫分型、染色体检查的临床资料,并结合治疗过程,对文献进行分析。结果该例患者的诊断结果符合B-PLL诊断标准,经FC方案牗氟达拉滨+环磷酰胺牘化学治疗牗简称化疗牘后曾获完全缓解,但后期复发耐药,经伊布替尼治疗再获缓解。结论B-PLL发病率低,针对复发难治病例,伊布替尼或是较好的治疗选择。Objective To investigate the mle of ibrutinib in the treatment of relapsed or reractory B-ell prolymphowytic leukenia(B-PL).MethodsThe clinical manifestations,bone marrow ell mompholog,immunotying and chromosome examination of a patient with B-PLL were retrospectively analyzed,and combined with the treatment proces,the lierature was analyzred.Results The patient was diag-nosed as B-PLA.After chemotherapy wih FC reginmen(fludarabine+cyclophosphamide),he had complete renmission,but then relapsedand dng resistance occumed in the later stage.He was relieved again after treatment with ibuprotimib.ConclusionThe incidence ofB-PLL is low and ibrutinib may be a better choice for relapsed or refractory cases.

关 键 词：幼淋巴细胞白血病 氟达拉滨 伊布替尼 临床疗效 

分 类 号：R969.3[医药卫生—药理学] R973[医药卫生—药学]